206 related articles for article (PubMed ID: 29329976)
1. Therapeutic potential of spinal GLP-1 receptor signaling.
Zhang D; Lv G
Peptides; 2018 Mar; 101():89-94. PubMed ID: 29329976
[TBL] [Abstract][Full Text] [Related]
2. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
[TBL] [Abstract][Full Text] [Related]
3. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway.
Kim DS; Choi HI; Wang Y; Luo Y; Hoffer BJ; Greig NH
Cell Transplant; 2017 Sep; 26(9):1560-1571. PubMed ID: 29113464
[TBL] [Abstract][Full Text] [Related]
4. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
Hölscher C
Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin improves functional recovery via GLP-1R-induced anti-apoptosis and facilitation of axonal regeneration after spinal cord injury.
Han W; Li Y; Cheng J; Zhang J; Chen D; Fang M; Xiang G; Wu Y; Zhang H; Xu K; Wang H; Xie L; Xiao J
J Cell Mol Med; 2020 Aug; 24(15):8687-8702. PubMed ID: 32573108
[TBL] [Abstract][Full Text] [Related]
6. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
[TBL] [Abstract][Full Text] [Related]
7. The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases.
Zhang L; Zhang W; Tian X
Int J Neurosci; 2023 May; 133(5):473-491. PubMed ID: 33941038
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
Al Batran R; Almutairi M; Ussher JR
Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
[TBL] [Abstract][Full Text] [Related]
9. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
Athauda D; Foltynie T
Drug Discov Today; 2016 May; 21(5):802-18. PubMed ID: 26851597
[TBL] [Abstract][Full Text] [Related]
10. The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway.
Li L
CNS Drugs; 2017 Jul; 31(7):535-549. PubMed ID: 28540646
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
Kopp KO; Glotfelty EJ; Li Y; Greig NH
Pharmacol Res; 2022 Dec; 186():106550. PubMed ID: 36372278
[TBL] [Abstract][Full Text] [Related]
12. Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced Behavior.
Harasta AE; Power JM; von Jonquieres G; Karl T; Drucker DJ; Housley GD; Schneider M; Klugmann M
Neuropsychopharmacology; 2015 Jul; 40(8):1969-78. PubMed ID: 25669605
[TBL] [Abstract][Full Text] [Related]
13. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
[TBL] [Abstract][Full Text] [Related]
14. Puerarin Protects Pancreatic β-Cells in Obese Diabetic Mice via Activation of GLP-1R Signaling.
Yang L; Yao D; Yang H; Wei Y; Peng Y; Ding Y; Shu L
Mol Endocrinol; 2016 Mar; 30(3):361-71. PubMed ID: 26789107
[TBL] [Abstract][Full Text] [Related]
15. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease.
Perry T; Greig NH
Curr Alzheimer Res; 2005 Jul; 2(3):377-85. PubMed ID: 15974903
[TBL] [Abstract][Full Text] [Related]
16. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
Nowell J; Blunt E; Gupta D; Edison P
Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
18. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
Bak AM; Egefjord L; Gejl M; Steffensen C; Stecher CW; Smidt K; Brock B; Rungby J
Expert Opin Ther Targets; 2011 Oct; 15(10):1153-62. PubMed ID: 21749267
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
Batista AF; Bodart-Santos V; De Felice FG; Ferreira ST
CNS Drugs; 2019 Mar; 33(3):209-223. PubMed ID: 30511349
[TBL] [Abstract][Full Text] [Related]
20. Mitral cells and the glucagon-like peptide 1 receptor: The sweet smell of success?
Bagnoli E; FitzGerald U
Eur J Neurosci; 2019 Feb; 49(4):422-439. PubMed ID: 30120857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
